# Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.

> **NCT01942213** · — · COMPLETED · sponsor: **Prism Vision Group** · enrollment: 136 (actual)

## Conditions studied

- Neovascular Age Related Macular Degeneration

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01942213
- **Lead sponsor:** Prism Vision Group
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2016-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01942213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01942213, "Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01942213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*